Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
The first GLP-1 receptor agonist approved by the FDA, originally derived from Gila monster saliva. Available in twice-daily (Byetta) and once-weekly (Bydureon) formulations. Paved the way for semaglutide and tirzepatide.
The first widely used GLP-1 receptor agonist for weight management, developed by Novo Nordisk. Predates semaglutide and tirzepatide. While largely superseded by newer agents for weight loss, it remains FDA-approved and widely prescribed, particularly for patients who tolerate it well or have established insurance coverage.
Synthetic version of exendin-4, a peptide found in Gila monster venom that shares 53% homology with human GLP-1 but resists DPP-4 degradation. Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety.
Activates GLP-1 receptors, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Requires daily injection due to a shorter half-life than semaglutide. The daily dosing schedule is both a limitation and, for some patients, a feature — easier to stop quickly if side effects occur.
- Type 2 diabetes
- Blood sugar regulation
- Modest weight loss
- Weight management (FDA-approved as Saxenda)
- Type 2 diabetes (FDA-approved as Victoza)
- Cardiovascular risk reduction
- Nausea (common, especially initially)
- Pancreatitis (rare)
- Injection site nodules (Bydureon)
- Renal impairment
- Thyroid C-cell tumors (animal studies)
- Nausea and vomiting (common, especially during titration)
- Pancreatitis risk
- Gallbladder disease
- Potential thyroid C-cell tumor risk (animal data)
- Daily injection burden vs. weekly alternatives
FDA-approved as Byetta (2005, twice daily) and Bydureon (2012, once weekly). The first-in-class GLP-1 agonist. Largely superseded by semaglutide for new prescriptions but still widely used.
FDA-approved as Victoza (type 2 diabetes, 2010) and Saxenda (weight management, 2014). The LEADER trial demonstrated cardiovascular risk reduction in diabetic patients. Largely superseded by semaglutide and tirzepatide for new prescriptions due to superior efficacy and weekly dosing, but remains a valid option with established long-term safety data.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.